Oramed Pharmaceuticals (ORMP) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Oramed Pharmaceuticals
Is Oramed Pharmaceuticals a buy right now? The alternative data says hold. This ORMP stock analysis is built on the 25+ alternative data signals AltIndex tracks on Oramed Pharmaceuticals every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 42/100: a Hold. The stock trades at $4.55 with a $187M market cap.
The data leans positive over the past 90 days — web traffic up 70.6% to 6K monthly visits — but the move hasn’t been broad enough to lift ORMP into buy territory yet.
ORMP’s broader alt-data profile also covers headcount (15 employees, according to LinkedIn), and Facebook followers (4K). Every signal links to its own page with full history, the ORMP technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ORMP is just below.
Oramed Pharmaceuticals AI Stock Analysis
Oramed Pharmaceuticals (NASDAQ: ORMP) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of novel drug delivery systems. The company's flagship product is an oral insulin capsule designed to provide an alternative to injectable insulin for managing diabetes.
Analysis generated October 2, 2026.
Recent Oramed Pharmaceuticals Stock Alerts
|
Oramed Pharmaceuticals | October 4 Insider Alert: Gabay Avraham is selling shares |
|
Oramed Pharmaceuticals | August 25 Price is up by 6.4% in the last 24h. |
|
Oramed Pharmaceuticals | August 3 Price is up by 6.4% in the last 24h. |
|
Oramed Pharmaceuticals | July 1 Price is down by -7.5% in the last 24h. |
Oramed Pharmaceuticals Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 6K | 70.6% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 15 | 0% | |
| Wikipedia Views | 5 | 25.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 4 | N/A | |
| Stocktwits Mentions | 0 | 100.0% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 5K | 0% | |
| X Followers | 2K | 0% | |
| Facebook Followers | 4K | 0% | |
| Facebook Engagement | 0 | N/A |
About Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
| Price | $4.55 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $187M |
| Year Range | $2 – $5 |
| Dividend Yield | 0% |
| PE Ratio | 1.1 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Oramed Pharmaceuticals News
View more → |
Congenital Hyperinsulinism Market to Expand at a CAGR of 12% During the Forecast Period (2026-2036) as Rising Disease Recognition and Novel Therapies Fuel Market Growth | DelveInsightAugust 26 - PRNewswire |
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic FinancingJuly 7 - GlobeNewswire |
|
 |
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetJune 25 - PRNewswire |
GLP-1 Receptor Agonist Market Projected to Reach USD 307 Billion by 2035 Driven by Expanding Metabolic Disease Burden – SNS InsiderMay 26 - GlobeNewswire |
|
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer - Global Forecast to 2030 and 2035May 21 - GlobeNewswire |
See Oramed Pharmaceuticals’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ORMP, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEOramed Pharmaceuticals Earnings & Financial Performance
View all earnings →Oramed Pharmaceuticals Insider Trading Activity
View all →| Hexter Joshua filed to sell 1,328,130 shares at $0.0. Oct 1 '26 |
| Gabay Avraham filed to sell 861,076 shares at $0.0. Oct 1 '26 |
| Gabay Avraham filed to sell 671,785 shares at $0.0. Jul 1 '26 |
| Hexter Joshua filed to sell 1,023,384 shares at $0.0. Jul 1 '26 |
Oramed Pharmaceuticals Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Brad Knott |
Feb 26, 25 | Sell | $33K+ |
| Andrew Garbarino |
Jan 14, 22 | Sell | $8K+ |
| Andrew Garbarino |
Nov 3, 21 | Sell | $8K+ |
Stocks Similar to Oramed Pharmaceuticals
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Cue BiopharmaCUE |
$24.36 4.7% | $186M | 61 |
 |
NkartaNKTX |
$2.53 1.8% | $184M | 32 |
 |
AdageneADAG |
$2.80 1.8% | $191M | 44 |
 |
Canton Strategic Holdings, Inc. - Common StockCNTN |
$2.33 3.6% | $179M | 55 |
 |
Coherus BioSciencesCHRS |
$1.12 3.5% | $179M | 33 |
Explore Oramed Pharmaceuticals Data
Frequently Asked Questions: Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals has an AltIndex AI Score of 42/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
42/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Oramed Pharmaceuticals (ORMP) stock is $4.55 with a market cap of $187M.
As of today, Oramed Pharmaceuticals’s PE (Price to Earnings) ratio is 1.1.
View the latest Oramed Pharmaceuticals insider transactions to see recent buying and selling activity by company executives and directors.
Check the Oramed Pharmaceuticals congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ORMP stock price chart above shows Oramed Pharmaceuticals’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Oramed Pharmaceuticals technical analysis for RSI, moving averages, and more.
See the stocks similar to Oramed Pharmaceuticals section on this page for companies in the same industry ranked by market cap and AI Score.
